OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Wagar on Lenvatinib Plus Pembrolizumab vs Chemo in First-Line Advanced Endometrial Cancer

March 5th 2025

Matthew Wagar, MD, discusses lenvatinib plus pembrolizumab vs chemotherapy as first-line treatment for advanced endometrial cancer.

Dr Shah on Disparities in Worldwide Bladder Cancer Trial Availability

March 5th 2025

Koral Shah, MD, details the rationale of evaluating worldwide disparities in bladder cancer clinical trial availability.

Dr Podoltsev on Blinatumomab Plus Consolidation Chemotherapy in Older BCR-ABL1–Negative ALL

March 4th 2025

Nikolai Podoltsev, MD, PhD, discusses the addition of blinatumomab to consolidation chemotherapy in older patients with newly diagnosed BCR-ABL1–negative ALL.

Dr Yang on Osimertinib Plus Savolitinib in MET-Aberrant, EGFR-Mutant Advanced NSCLC

March 4th 2025

Jin-Ji Yang, MD, discusses osimertinib plus savolitinib as a first-line treatment in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Dr Raghav on the Safety Profile of ABBV-400 Plus Chemo and Bevacizumab in Previously Treated mCRC

March 4th 2025

Kanwal P.S. Raghav, MBBS, MD, details the preliminary safety of a ABBV-400 regimen for the treatment of patients with previously treated mCRC.

Dr Lee on the Rationale for Using Integrative Medicine in Patients With GI Cancers

March 4th 2025

Richard T. Lee, MD, discusses research showing the benefits of acupuncture, ginger, and ginseng for improving symptoms in patients with GI cancers.

Dr Vlachou on Primary Tumor Responses With Enfortumab Vedotin in Upper Tract Urothelial Cancer

March 4th 2025

Evangelia Vlachou, MD, discusses response rates with enfortumab vedotin alone or with pembrolizumab in patients with upper tract urothelial cancer.

Dr Zhou on Frontline Ivonescimab vs Pembrolizumab in PD-L1+ Advanced NSCLC

March 3rd 2025

Caicun Zhou, MD, PhD, discusses data for ivonescimab vs pembrolizumab as first-line treatment for patients with PD-L1–positive advanced NSCLC.

Dr Shroff on the Addition of Nab-Paclitaxel to Gemcitabine/Cisplatin in Biliary Tract Cancer

March 3rd 2025

Rachna Shroff, MD, MS, FASCO, discusses the efficacy of nab-paclitaxel plus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancer.

Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL

March 3rd 2025

Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.

Dr Jain on Existing Challenges Within the TNBC Treatment Paradigm

March 3rd 2025

Angela Jain, MD, details ongoing challenges with identifying optimal treatments for patients with triple-negative breast cancer.

Dr Shah on the Rationale for Evaluating Zamto-Cel in R/R DLBCL

March 1st 2025

Nirav N. Shah, MD, discusses how zamto-cel might address resistance to prior CD19-directed therapy in patients with relapsed/refractory DLBCL.

Dr Chiorean on Encorafenib Plus Cetuximab for BRAF V600E–Mutated mCRC

February 28th 2025

E. Gabriela Chiorean, MD, FASCO, discusses the FDA approval of encorafenib plus cetuximab and chemotherapy for patients with BRAF V600E–mutated mCRC.

Dr Nayak on the Ongoing Investigation of Emavusertib Plus Ibrutinib in R/R PCNSL

February 28th 2025

Lakshmi Nayak, MD, discusses the mechanism of action of emavusertib and the study of this drug relapsed/refractory primary and secondary CNS lymphoma.

Dr Li on the Casdozokitug/Atezolizumab/Bevacizumab in Unresectable HCC

February 28th 2025

Daneng Li, MD, discusses a trial evaluating casdozokitug plus atezolizumab and bevacizumab in unresectable, locally advanced or metastatic HCC.

Dr Smaglo on Selecting Between Frontline Chemotherapy Regimens for Pancreatic Cancer

February 28th 2025

Brandon G. Smaglo, MD, FACP, discusses considerations for choosing between frontline chemotherapy-based regimens for patients with pancreatic cancer.

Dr Beckermann on the Role of Tivozanib in Advanced Clear Cell RCC

February 28th 2025

Kathryn E. Beckermann, MD, PhD, details the role of tivozanib as second- and third-line therapy in patients with locally advanced or metastatic ccRCC.

Dr Winer on the Efficacy of Emavusertib in AML With FLT3 and Spliceosome Factor Mutations

February 28th 2025

Eric S. Winer, MD, discusses the efficacy of emavusertib in patients with relapsed/refractory AML harboring FLT3 and/or spliceosome factor mutations.

Dr Ebrahimi on Clinical Outcomes With the Addition of CBM588 to Cabozantinib and Nivolumab in RCC

February 27th 2025

Hedyeh Ebrahimi, MD, MPH, discusses clinical outcomes with CBM588 plus cabozantinib and nivolumab in metastatic renal cell carcinoma.

Dr Kitko on Clinical Outcomes With Axatilimab According to Prior Lines of Therapy for Chronic GVHD

February 27th 2025

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.